News Center

Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy, highlighting favorable efficacy and safety outcomes. After 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to 20% for Valchlor, with greater average improvement and no treatment-related adverse events reported for HyBryte, while Valchlor patients experienced multiple adverse […]

Datavault AI (NASDAQ: DVLT), an AI-driven data monetization, RWA tokenization and Web 3.0 infrastructure company, and Demora Foundation announced a Technology Integration Agreement naming Datavault AI as the formal AI data intelligence and RWA tokenization technology partner for the K-Entertainment & K-Wave Global Platform, spanning Atlanta, Dallas and the New York Tri-State area. Under the […]

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance […]

Beeline Holdings (NASDAQ: BLNE),  a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, reported strong revenue growth and improving loan economics in its recently reported fourth-quarter 2025 results, highlighting a strategy that combines digital mortgage origination with new fee-based real-estate finance products. The fintech lender posted net revenue of $2.5 million in […]

Cardio Diagnostics Holdings (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators. At the core of its strategy […]

Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for dusquetide […]

Datavault AI (NASDAQ: DVLT) announced the closing of a definitive agreement with Coppercore Inc. to digitize and tokenize copper resources through its proprietary blockchain platform, targeting the creation of $100 million or more in Coppercoin(TM) digital tokens. Each token will represent five pounds of in-ground copper with pricing linked to COMEX benchmarks, enabling fractional, liquid ownership […]

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing… […]